

Special Issue

The Current Development of Glycoconjugate Vaccines for Infectious Diseases

Message from the Guest Editor

Glycoconjugate vaccines were successful against *H. influenzae* b (Hib) in the 1980s, leading to the development of other conjugate vaccines. However, chemical conjugation has limitations such as variability, high costs, and low recovery. Biological conjugation, such as glycoengineering of recombinant vaccines in bacteria, bypasses these issues. Another alternative method is using Multiple Antigen Presenting Systems (MAPS) to produce glycoconjugate vaccines. This special issue highlights recent scientific knowledge and progress in the field of conjugate vaccines. In this special issue on conjugate vaccines, we invite you to contribute an original report, observation, or review. Your contribution should focus on the development and evaluation of conjugate vaccines against infectious diseases, novel carrier proteins, recent advances in production technologies, and improvements in characterization methods. Specifically,

- development and evaluation of conjugate vaccines against infectious diseases,
- novel carrier proteins,
- recent advances in novel technologies for conjugate vaccine production,
- improvements in methods for conjugate vaccine characterization.

Guest Editor

Dr. Fatme Mawas

Vaccines Division, Science, Research & Innovation Group, MHRA,
Potters Bar, UK

Deadline for manuscript submissions

30 September 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/192527

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).